{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:09Z","timestamp":1789745409838,"version":"4.0.1"},"reference-count":107,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Polycythemia vera (PV) belongs to the BCR-ABL1\u2013negative myeloproliferative neoplasms and is characterized by activating mutations in JAK2 and clinically presents with erythrocytosis, variable degrees of systemic and vasomotor symptoms, and an increased risk of both thromboembolic events and progression to myelofibrosis and acute myeloid leukemia (AML). Treatment selection is based on a patient\u2019s age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-\u03b1) is added for high-risk disease. However, other disease features such as significant disease-related symptoms and splenomegaly, concurrent thrombocytosis and leukocytosis, or intolerance of phlebotomy can constitute an indication for cytoreductive therapy in patients with otherwise low-risk disease. Additionally, recent studies demonstrating the safety and efficacy (ie, reduction in phlebotomy requirements and molecular responses) of ropegylated IFN-\u03b12b support its use for patients with low-risk PV. Additionally, emerging data suggest that early treatment is associated with higher rates of molecular responses, which might eventually enable time-limited therapy. Nonetheless, longer follow-up is needed to assess whether molecular responses associate with clinically meaningful outcome measures such as thrombosis and progression to myelofibrosis or AML. In this article, we provide an overview of the current and evolving treatment landscape of PV and outline our vision for a patient-centered, phlebotomy-free, treatment approach using time-limited, disease-modifying treatment modalities early in the disease course, which could ultimately affect the natural history of the disease.<\/jats:p>","DOI":"10.1182\/blood.2023021503","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:14:23Z","timestamp":1695240863000},"page":"1859-1870","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Moving toward disease modification in polycythemia vera"],"prefix":"10.1182","volume":"142","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[{"name":"1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"How","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2023113016210619900_bib1","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"17","key":"2023113016210619900_bib2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023113016210619900_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023113016210619900_bib4","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2023113016210619900_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2023113016210619900_bib6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2023113016210619900_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"3","key":"2023113016210619900_bib8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ajh.26821","article-title":"The International Consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2023113016210619900_bib91","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.rpth.2023.100132","article-title":"Prediction of thrombosis in polycythemia vera: development and validation of a multiple factor-based prognostic score system","volume":"7","author":"Gu","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2023113016210619900_bib92","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"2023113016210619900_bib93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5045\/br.2021.2021089","article-title":"Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden","volume":"56","author":"Lee","year":"2021","journal-title":"Blood Res"},{"issue":"1","key":"2023113016210619900_bib94","doi-asserted-by":"crossref","first-page":"17819","DOI":"10.1038\/s41598-021-97464-4","article-title":"Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"2023113016210619900_bib95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hon.2843","article-title":"Impact of comorbidities and body mass index on the outcome of polycythemia vera patients","volume":"39","author":"Benevolo","year":"2021","journal-title":"Hematol Oncol"},{"issue":"6","key":"2023113016210619900_bib96","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"2023113016210619900_bib97","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2021-147869","article-title":"A JAK2V617F variant allele frequency greater than 50% identifies patients with polycythemia vera at high risk for venous thrombosis [abstract]","volume":"138","author":"Loscocco","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023113016210619900_bib98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency &gt;50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2023113016210619900_bib99","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2021-148020","article-title":"European Leukemianet (ELN) response predicts disease progression but not thrombosis or death in polycythemia vera (PV): an analysis of a multicenter database [abstract]","volume":"138","author":"Tremblay","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023113016210619900_bib100","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/cancers12040934","article-title":"Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A\/TET2\/ASXL1 mutations","volume":"12","author":"Segura-D\u00edaz","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2023113016210619900_bib101","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2023113016210619900_bib17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"19","key":"2023113016210619900_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023113016210619900_bib79","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2023113016210619900_bib102","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023113016210619900_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023113016210619900_bib66","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023113016210619900_bib103","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A\u00a0reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2023113016210619900_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023113016210619900_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"2023113016210619900_bib104","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","article-title":"Polycythemia vera: gender-related phenotypic differences","volume":"7","author":"Landolfi","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"suppl 1","key":"2023113016210619900_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-134583","article-title":"Symptom burden in \u201clow risk PV\u201d frequently is problematic and may justify earlier intervention with cytoreductive therapy: an MPN-QOL Study Group study [abstract]","volume":"136","author":"Mesa","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2023113016210619900_bib13","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1182\/blood.V126.23.5187.5187","article-title":"Burden of phlebotomy in patients with polycythemia vera in the United States: baseline data from the REVEAL study","volume":"126","author":"Boccia","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2023113016210619900_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-142549","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients: a retrospective analysis between 2018-2019 in US population [abstract]","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2023113016210619900_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann Hematol"},{"issue":"7834","key":"2023113016210619900_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"8","key":"2023113016210619900_bib20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","article-title":"Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia","volume":"95","author":"Antonioli","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2023113016210619900_bib21","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"20","key":"2023113016210619900_bib22","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"Podoltsev","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2023113016210619900_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"2023113016210619900_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2023113016210619900_bib25","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood-2021-150491","article-title":"Clonal dynamics of JAK2V617F and non-driver mutations in polycythemia vera and essential thrombocythemia patients receiving hydroxyurea therapy [abstract]","volume":"138","author":"Fern\u00e1ndez-Ibarrondo","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023113016210619900_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3109\/10428194.2013.827788","article-title":"Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea","volume":"55","author":"Verner","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023113016210619900_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"2023113016210619900_bib28","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4 pt 2","key":"2023113016210619900_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"2023113016210619900_bib30","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A\u00a0randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2023113016210619900_bib31","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3390\/cancers14225495","article-title":"Recombinant interferon-\u03b2 in the treatment of polycythemia vera and related neoplasms: rationales and perspectives","volume":"14","author":"Hasselbalch","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023113016210619900_bib32","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2023113016210619900_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3324\/haematol.2021.280080","article-title":"Conventional interferon-\u03b1 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center","volume":"107","author":"Liu","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"2023113016210619900_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2023113016210619900_bib35","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2023113016210619900_bib44","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"2023113016210619900_bib42","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023113016210619900_bib105","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"18","key":"2023113016210619900_bib40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2023113016210619900_bib106","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023113016210619900_bib45","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2023113016210619900_bib37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood-2018-99-111255","article-title":"Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the Daliah Trial - a randomized controlled phase III clinical trial [abstract]","volume":"132","author":"Knudsen","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2023113016210619900_bib38","doi-asserted-by":"crossref","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2023113016210619900_bib39","doi-asserted-by":"crossref","first-page":"e28888","DOI":"10.1002\/pbc.28888","article-title":"Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia","volume":"68","author":"Kucine","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2023113016210619900_bib41","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(21)00343-4","article-title":"Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials","volume":"9","author":"Mazza","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023113016210619900_bib43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res"},{"issue":"6","key":"2023113016210619900_bib46","doi-asserted-by":"crossref","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evidence"},{"issue":"suppl 1","key":"2023113016210619900_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-141223","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission [abstract]","volume":"136","author":"Daltro De Oliveira","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2023113016210619900_bib48","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2023113016210619900_bib49","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023113016210619900_bib50","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"key":"2023113016210619900_bib51","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"2023113016210619900_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2016","journal-title":"Eur J Haematol"},{"issue":"8","key":"2023113016210619900_bib53","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","article-title":"The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms","volume":"58","author":"Skov","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2023113016210619900_bib54","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood.V96.13.4313","article-title":"Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells","volume":"96","author":"Xu","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2023113016210619900_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"6","key":"2023113016210619900_bib56","doi-asserted-by":"crossref","first-page":"e0270669","DOI":"10.1371\/journal.pone.0270669","article-title":"Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms","volume":"17","author":"Skov","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"2023113016210619900_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2023113016210619900_bib59","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon \u03b1-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2023113016210619900_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020005792","article-title":"Germline genetic factors influence the outcome of interferon-\u03b1 therapy in polycythemia vera","volume":"137","author":"J\u00e4ger","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023113016210619900_bib61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023113016210619900_bib62","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023113016210619900_bib63","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023113016210619900_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2023113016210619900_bib65","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2019-123985","article-title":"Ruxolitinib shows efficacy in patients with newly-diagnosed polycythemia vera: futility analysis of the randomized Ruxo-BEAT clinical trial of the German Study Group for myeloproliferative neoplasms [abstract]","volume":"134","author":"Koschmieder","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2023113016210619900_bib67","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2023113016210619900_bib68","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"16","key":"2023113016210619900_bib69","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2023113016210619900_bib71","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2023113016210619900_bib72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10428194.2016.1187269","article-title":"Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea","volume":"58","author":"Douglas","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023113016210619900_bib73","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"5","key":"2023113016210619900_bib74","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1038\/bcj.2016.34","article-title":"Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience","volume":"6","author":"Begna","year":"2016","journal-title":"Blood Cancer J"},{"issue":"12","key":"2023113016210619900_bib10","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"Tefferi","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2023113016210619900_bib75","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"Sorensen","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023113016210619900_bib76","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1182\/blood-2022-157397","article-title":"Combination therapy with ruxolitinib and interferon in newly diagnosed patients with polycythemia vera [abstract]","volume":"140","author":"S\u00f8rensen","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023113016210619900_bib77","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2021-149205","article-title":"Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy [abstract]","volume":"138","author":"Ginzburg","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"2023113016210619900_bib78","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","article-title":"Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients","volume":"40","author":"Hoffman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2023113016210619900_bib80","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/blood-2022-163755","article-title":"Verify: a phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera [abstract]","volume":"140","author":"Verstovsek","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2023113016210619900_bib81","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in\u00a0vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2023113016210619900_bib82","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2023113016210619900_bib83","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043","article-title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"2023113016210619900_bib84","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1182\/bloodadvances.2020002379","article-title":"Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin","volume":"4","author":"Marcellino","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2023113016210619900_bib85","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"2023113016210619900_bib86","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023113016210619900_bib87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2023113016210619900_bib107","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"33","key":"2023113016210619900_bib108","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023113016210619900_bib109","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1002\/cam4.3380","article-title":"Depressive symptoms and myeloproliferative neoplasms: understanding the confounding factor in a complex condition","volume":"9","author":"Padrnos","year":"2020","journal-title":"Cancer Med"},{"issue":"10","key":"2023113016210619900_bib110","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the International MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"issue":"21","key":"2023113016210619900_bib88","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023113016210619900_bib89","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2023113016210619900_bib90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/22\/1859\/2091046\/blood_bld-2023-021503-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/22\/1859\/2091046\/blood_bld-2023-021503-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T16:21:57Z","timestamp":1701361317000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/22\/1859\/497955\/Moving-toward-disease-modification-in-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":107,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021503","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}